- Home
- CUBA vs ANTX Comparison
CUBA vs ANTX Comparison
Compare CUBA & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBA
- ANTX
- Stock Information
- Founded
- CUBA 1992
- ANTX 2017
- Country
- CUBA United States
- ANTX United States
- Employees
- CUBA N/A
- ANTX N/A
- Industry
- CUBA Investment Managers
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CUBA Finance
- ANTX Health Care
- Exchange
- CUBA Nasdaq
- ANTX Nasdaq
- Market Cap
- CUBA 38.8M
- ANTX 40.0M
- IPO Year
- CUBA N/A
- ANTX 2022
- Fundamental
- Price
- CUBA $2.46
- ANTX $1.27
- Analyst Decision
- CUBA
- ANTX Hold
- Analyst Count
- CUBA 0
- ANTX 5
- Target Price
- CUBA N/A
- ANTX $3.50
- AVG Volume (30 Days)
- CUBA 93.9K
- ANTX 387.1K
- Earning Date
- CUBA 01-01-0001
- ANTX 11-13-2024
- Dividend Yield
- CUBA 20.83%
- ANTX N/A
- EPS Growth
- CUBA N/A
- ANTX N/A
- EPS
- CUBA N/A
- ANTX N/A
- Revenue
- CUBA N/A
- ANTX N/A
- Revenue This Year
- CUBA N/A
- ANTX N/A
- Revenue Next Year
- CUBA N/A
- ANTX N/A
- P/E Ratio
- CUBA N/A
- ANTX N/A
- Revenue Growth
- CUBA N/A
- ANTX N/A
- 52 Week Low
- CUBA $2.25
- ANTX $0.87
- 52 Week High
- CUBA $4.14
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- CUBA 53.05
- ANTX 43.86
- Support Level
- CUBA $2.39
- ANTX $1.23
- Resistance Level
- CUBA $2.49
- ANTX $1.59
- Average True Range (ATR)
- CUBA 0.04
- ANTX 0.08
- MACD
- CUBA -0.00
- ANTX -0.04
- Stochastic Oscillator
- CUBA 70.00
- ANTX 8.11
About CUBA Herzfeld Caribbean Basin Fund Inc. (The)
Herzfeld Caribbean Basin Fund Inc operates as a closed-end management investment company. The company's investment objective is to obtain long-term capital appreciation. The firm offers customized discretionary account management and fund management services to individual and institutional investors. The fund invests in equity and equity-linked securities of public and private companies, including United States-based companies, whose securities are traded principally on a stock exchange in a Caribbean Basin Country. The fund's revenue source is through the dividends it receives. Its investments are geographically allocated in the United States followed by Mexico, Puerto Rico, and other countries.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.